Participate in Research at CU Anschutz

This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

You are being asked to be in this research study because you are an adult with advanced melanoma (a kind of skin cancer) that has spread or cannot be surgically removed. This study includes participants with advanced melanoma from any part of the body except the eye. This study plans to learn more about if the study drug (IMC-F106C), in combination with a standard therapy (nivolumab), works better than the standard therapy (nivolumab alone or in combination with relatlimab) at making tumors stop growing (or shrink). A second purpose is to better understand the safety of IMC-F106C in combination with nivolumab and to learn whether a lower or higher dose of IMC-F106C in combination with this standard therapy works better and/or is safer. This study will also look at how well you feel after you receive the study drug or the standard therapy.